Loading...
Loading...
Pfizer Inc.
PFE and Merck & Co. Inc.
MRK, known as MSD outside
the United States and Canada, through a subsidiary, announced today that they
have entered into an agreement to explore the therapeutic potential of the
combination of Pfizer's crizotinib (XALKORI^®) with Merck's investigational
anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the
safety and tolerability of the combination in patients with ALK-positive
advanced or metastatic non-small cell lung cancer (NSCLC). The financial terms
of the agreement were not disclosed.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in